Therapeutic vaccination trials, in which patients with cancer were vaccinated with minimal
CTL peptide in oil-in-water formulations, have met with limited success. Many of these …

Anti‐tumor vaccines consisting of extended CTL peptides in combination with CpG‐ODN
were shown to be superior to those comprising minimal CTL epitopes and CpG‐ODN, in that …

Vaccines consisting of synthetic peptides representing cytotoxic T-lymphocyte (CTL)
epitopes have long been considered as a simple and cost-effective approach to treat cancer …

The identification of CTL-defined tumor-associated Ags has allowed the development of new
strategies for cancer immunotherapy. To potentiate the CTL responses, peptide-based …

At the beginning of this new millennium, pathogens and cancer remain the leading causes
of death worldwide. The development of vaccines to prevent diseases for which no vaccine …

Synthetic peptide-based vaccines have been shown to induce potent protective and
therapeutic T cell-mediated immunity in preclinical animal models and are now being …

The antigen processing‐defective mutant cell line RMA‐S expresses at the cell surface
major histocompatibility complex (MHC) class I molecules devoid of peptide that can be …

Construction of an optimal vaccine against tumors relies on the availability of appropriate
tumor-specific antigens capable to stimulate CD4+ T helper cells (TH) and CD8+ cytolytic T …

Different strategies based on peptides are available for cancer treatment, in particular to
counter-act the progression of tumor growth and disease relapse. In the last decade, in the …

Although numerous studies have documented a role for B7-1 (CD80) in the induction of
antitumor CTL immunity, it is presently unclear to what extent expression of this …